08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

BioProgress, airPharma LLC, Zentiva N.V. deal

BPRG will acquire 10 marketed generic products for respiratory disease from airPharma for $4 million in upfront cash and $4 million in two tranches of stock payments, the latter being contingent on certain sales milestones....
08:00 , Nov 6, 2006 |  BioCentury  |  Finance

Ebb & Flow

When New Leaf (then Sprout), Venrock and Oxford BioScience first looked into Ribozyme Pharmaceuticals in late 2002, the eponymous biotech was on the ropes. It had a market cap of just over $5 million and...
01:18 , Oct 31, 2006 |  BC Extra  |  Financial News

BioProgress raises L6.2M, acquires airPharma products

Drug delivery company BioProgress (LSE:BPRG; BPRG) raised L6.2 million ($11.7 million) in a private placement of 12.3 million shares at 50p, a 22% discount to Friday's close of 64.17p. BPRG said it will use the...
08:00 , Feb 6, 2006 |  BioCentury  |  Product Development

Emerging asthma treatments

Emerging asthma treatments Company Product Description Target Status Genentech/Tanox/ Novartis Xolair omalizumab Humanized MAb against IgE IgE Mkt (adults/ adolescents); Ph III(pediatric) Altana Daxas roflumilast Phosphodiesterase-4 (PDE-4) inhibitor PDE-4 Ph III; MAA withdrawn in Nov...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Company News

airPharma, Bespak plc deal

BPK will develop and manufacture an inhalation device for airPharma's dry powder formulation of Zofac pumactant. airPharma plans to begin Phase II testing of the product in asthma this year. airPharma,...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Company News

airPharma management update

airPharma, Overland Park, Kan.   Business: Pulmonary   Hired: Peter Higuchi as VP of corporate development, formerly president and CEO of Cydex Inc.; and Ed Mitchell as VP of product development, formerly North American head of industrial...
08:00 , Nov 15, 2004 |  BC Week In Review  |  Company News

airPharma, Britannia deal

airPharma received an exclusive global development and marketing license to AP0016 for all respiratory/pulmonary indications. The compound is a dry powder formulation of Britannia's protein-free synthetic surfactant Pumactant. airPharma will be responsible...
08:00 , Nov 9, 2004 |  BC Extra  |  Company News

airPharma, Britannia asthma deal

airPharma (Overland Park, Kan.) received a global development license to AP0016, a dry powder formulation of Britannia's protein-free synthetic surfactant, Pumactant. airPharma will be responsible for all development and regulatory and marketing activities, except in...